Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Antitumor immunity against hCG&bgr; induced by a tumor cell vaccine modified with a fusion gene of hCG&bgr; and polyarginines

Date

10 Oct 2016

Session

Poster display

Presenters

Yan Zhang

Citation

Annals of Oncology (2016) 27 (6): 1-14. 10.1093/annonc/mdw362

Authors

Y. Zhang1, C. Su2, Y. Wang1, Y. Lu1, Y. Wei1

Author affiliations

  • 1 Thoracic Oncology, Cancer Center And State Key Laboratory Of Biotherapy, West China Hospital, West China Medical School, Sichuan University, 610041 - Chengdu/CN
  • 2 State Key Laboratory Of Biotherapy, West China Hospital, Sichuan University, Chengdu/CN
More

Resources

Abstract 2760

Background

Human chorionic gonadotropin ß (hCGß) is a kind of pregnancy hormones, moreover, it is a tumor-associated antigen ectopically expressed on a variety of human non-trophoblastic tumors such as pancreatic cancer, bladder cancer and lung cancer. Therefore, hCGß is considered as an ideal target antigen. However, as a self-antigen, hCGß is tolerated by the immune system and immune response is hardly induced. 9-mer of L-arginine (Arg9), a type of cell penetrating peptide, can play an important role in the translocation process.

Methods

Firstly, we designed and constructed two eukaryotic expressing plasmids including pCDNA3.1-hCGß-Arg9 (phCGß-Arg9) and pCDNA3.1-hCGß (phCGß). Secondly, B16.E5, a B16 cell line expressing hCGß, was acquired by transfected B16-F10 cells with phCGß and selected with G418. Meanwhile we constructed hCGß-Arg9 gene modified tumor cell vaccine by transient transfection of phCGß-Arg9 into B16-F10 cells with liposome. Finally, we took the prophylactic vaccination experiment in vivo to investigate the protective efficacy and the immune mechanisms.

Results

The transfectant with highest expression of hCGß was screened and named B16.E5 as a tumor model in this experiment. The results of protective experiment demonstrated 60% mice of hCGß-Arg9 group were protected from the challenge of B16.E5 cells. Moreover, survival benefit was also observed in mice vaccinated with the hCGß-Arg9 tumor vaccine (48.4 ± 4.9 days) compared with controls. Then, the experiments for immune mechanism were conducted, including T lymphocytes adoptive transfer experiment, CTL-mediated cytotoxicity analysis, hCGß antibody tests of serum after vaccination and serum transfer analysis. All of these suggested cellular immunity, rather than humoral immunity, may play the major role in the antitumor activity.

Conclusions

We designed and constructed the tumor cell vaccine modified with hCGß-Arg9 gene and demonstrated that this vaccine can induce cellular immunity, through which the vaccine can play protective efficacy in animal experiments. Our work may contribute to designing novel generation of tumor vaccines.

Clinical trial identification

Legal entity responsible for the study

Department of Thoracic Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, China

Funding

National Natural Science Funds of China (81402561)

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings